MX2020001501A - Streptococcus australis como bioterapeuticos. - Google Patents
Streptococcus australis como bioterapeuticos.Info
- Publication number
- MX2020001501A MX2020001501A MX2020001501A MX2020001501A MX2020001501A MX 2020001501 A MX2020001501 A MX 2020001501A MX 2020001501 A MX2020001501 A MX 2020001501A MX 2020001501 A MX2020001501 A MX 2020001501A MX 2020001501 A MX2020001501 A MX 2020001501A
- Authority
- MX
- Mexico
- Prior art keywords
- biotherapeutics
- streptococcus australis
- probiotics
- compositions
- australis
- Prior art date
Links
- 241000176094 Streptococcus australis Species 0.000 title abstract 2
- 229940126587 biotherapeutics Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 239000006041 probiotic Substances 0.000 abstract 2
- 235000018291 probiotics Nutrition 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La descripción se refiere a productos bioterapéuticos vivos, probióticos, composiciones farmacéuticas que comprenden dichos probióticos, y métodos para usarlos para tratar diversas enfermedades humanas. En algunos aspectos, la descripción proporciona tales composiciones que comprenden cepas de la bacteria Streptococcus australis y sus usos en el tratamiento de enfermedades o trastornos relacionados con el metabólico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762541759P | 2017-08-06 | 2017-08-06 | |
PCT/US2018/045330 WO2019032432A1 (en) | 2017-08-06 | 2018-08-06 | STREPTOCOCCUS AUSTRALIS AS A BIOTHERAPEUTIC AGENT |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001501A true MX2020001501A (es) | 2020-03-24 |
Family
ID=65272764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001501A MX2020001501A (es) | 2017-08-06 | 2018-08-06 | Streptococcus australis como bioterapeuticos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US11389487B2 (es) |
EP (1) | EP3662087B1 (es) |
JP (1) | JP2020530011A (es) |
KR (1) | KR20200037292A (es) |
CN (1) | CN111050782A (es) |
AU (1) | AU2018314228A1 (es) |
CA (1) | CA3072289A1 (es) |
MX (1) | MX2020001501A (es) |
SG (1) | SG11202001051SA (es) |
WO (1) | WO2019032432A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020530011A (ja) | 2017-08-06 | 2020-10-15 | セカンド ゲノム インコーポレイテッド | バイオ治療薬としてのストレプトコッカス・オーストラリス(Streptococcus australis) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4580542B2 (ja) | 2000-05-17 | 2010-11-17 | 株式會社バイオニア | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 |
PL2808024T3 (pl) * | 2009-06-19 | 2019-09-30 | Dupont Nutrition Biosciences Aps | Bifidobakterie do leczenia zastoinowej niewydolności serca |
RU2013133994A (ru) * | 2010-12-21 | 2015-01-27 | Нестек С.А. | Способы и композиции, применимые для контроля глюкозы в крови животных |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
BR112015018625A2 (pt) * | 2013-02-04 | 2017-09-19 | Seres Therapeutics Inc | composições e métodos |
AU2014232370B2 (en) * | 2013-03-15 | 2018-11-01 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
CA2986203A1 (en) | 2015-05-21 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Bacterial populations for promoting health |
US20170172167A1 (en) | 2015-07-23 | 2017-06-22 | Medela Holding Ag | Infant feed and method |
JP2020530011A (ja) | 2017-08-06 | 2020-10-15 | セカンド ゲノム インコーポレイテッド | バイオ治療薬としてのストレプトコッカス・オーストラリス(Streptococcus australis) |
-
2018
- 2018-08-06 JP JP2020506762A patent/JP2020530011A/ja active Pending
- 2018-08-06 EP EP18843572.1A patent/EP3662087B1/en active Active
- 2018-08-06 CN CN201880050856.6A patent/CN111050782A/zh active Pending
- 2018-08-06 SG SG11202001051SA patent/SG11202001051SA/en unknown
- 2018-08-06 US US16/637,068 patent/US11389487B2/en active Active
- 2018-08-06 AU AU2018314228A patent/AU2018314228A1/en not_active Abandoned
- 2018-08-06 MX MX2020001501A patent/MX2020001501A/es unknown
- 2018-08-06 KR KR1020207004937A patent/KR20200037292A/ko unknown
- 2018-08-06 WO PCT/US2018/045330 patent/WO2019032432A1/en active Application Filing
- 2018-08-06 CA CA3072289A patent/CA3072289A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3662087B1 (en) | 2022-10-05 |
JP2020530011A (ja) | 2020-10-15 |
EP3662087A4 (en) | 2020-09-09 |
KR20200037292A (ko) | 2020-04-08 |
CA3072289A1 (en) | 2019-02-14 |
US11389487B2 (en) | 2022-07-19 |
EP3662087A1 (en) | 2020-06-10 |
US20200237829A1 (en) | 2020-07-30 |
WO2019032432A1 (en) | 2019-02-14 |
SG11202001051SA (en) | 2020-03-30 |
CN111050782A (zh) | 2020-04-21 |
AU2018314228A1 (en) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY186217A (en) | Mixture of hmos | |
SA520411910B1 (ar) | تركيبات وطرق لعلاج اضطرابات مناعية باستخدام سلالات بكتيرية من المكورات اللبنية المعدلة للمناعة | |
PH12017501342A1 (en) | Glycan therapeutics and related methods thereof | |
MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
MX2022000056A (es) | Peptidos anti-microbianos estabilizados. | |
MX2016014807A (es) | Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados. | |
MX2018000870A (es) | Metodos y materiales para mejorar las respuestas inmunitarias y funciones de la barrera de piel y/o mucosa. | |
WO2017136795A8 (en) | Bacteria engineered to treat diseases associated with tryptophan metabolism | |
WO2016183532A8 (en) | Bacteria engineered to treat a disease or disorder | |
CL2019002640A1 (es) | Moléculas propioticas para reducir virulencia de patógenos. | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
MX2021016034A (es) | Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella. | |
WO2017139697A8 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
WO2016210384A3 (en) | Bacteria engineered to treat metabolic diseases | |
WO2016200614A3 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
CN107405369A8 (zh) | 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法 | |
MX2018004616A (es) | Cosmetica qie tiene bacterias probioticas. | |
MX2019002924A (es) | Composiciones purificadas de oligosacaridos de leche humana. | |
WO2017200873A8 (en) | COMPOSITIONS AND METHODS FOR TREATING ACNE | |
PH12019550265A1 (en) | Composition comprising mannose oligosaccharide and process for making same and use thereof | |
PH12018550110A1 (en) | Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation | |
MX2018008645A (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
NZ745187A (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
WO2017123610A3 (en) | Bacteria engineered to detoxify deleterious molecules | |
PH12019550183A1 (en) | Treatment of infant colic |